Clinical Trials
35 trialsNCT07217171 2026-06-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
Phase 1 Recruiting
NCT07284186 2026-05-29
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
Phase 1 Recruiting
NCT07085091 2026-05-12
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology Inc.
Phase 1 Recruiting
NCT04389632 2026-05-11
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT05799274 2026-05-05
RAD301
Radiopharm Theranostics, Ltd
Phase 1 Recruiting
NCT07218003 2026-05-04
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Phase 1 Enrolling by invitation
NCT04460937 2026-04-29
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05208762 2026-04-20
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT03114319 2026-04-16
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT07229313 2026-04-16
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
Phase 1 Recruiting
NCT06545331 2026-04-15
DELTA-101
Exelixis
Phase 1 Recruiting
NCT07090499 2026-04-07
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT06657144 2026-04-06
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Recruiting
NCT07277413 2026-04-03
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Recruiting
NCT06654297 2026-04-02
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
West China Hospital
Phase 1 Active not recruiting
NCT07503808 2026-03-31
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
Phase 1 Recruiting
NCT05462873 2026-02-17
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT06242470 2026-02-05
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Recruiting
NCT06560645 2026-02-02
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 1 Terminated
NCT07359417 2026-01-22
ESCALATE
UMC Utrecht
Phase 1 Recruiting
NCT06084481 2026-01-20
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
Phase 1 Active not recruiting
NCT06781983 2026-01-07
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
Phase 1 Recruiting
NCT07317609 2026-01-05
Endosurgery-02
Shanghai Zhongshan Hospital
Phase 1 Recruiting
NCT04045496 2025-12-29
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1 Completed
NCT06549816 2025-12-15
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Seagen Inc.
Phase 1 Completed
NCT05427396 2025-12-03
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT03983954 2025-11-28
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Phase 1 Active not recruiting
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT07203898 2025-10-02
A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.
Beijing Immupeutics Medicine Technology Limited
Phase 1 Not yet recruiting
NCT04000529 2025-09-30
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
Phase 1 Terminated
NCT07154108 2025-09-04
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
Sichuan University
Phase 1 Not yet recruiting
NCT03708328 2025-08-20
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT06020885 2025-07-21
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
Sun Yat-sen University
Phase 1 Active not recruiting
NCT04242199 2025-07-14
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT01351103 2025-06-13
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis
Phase 1 Completed